Mesoblast (MSB.AX) (OTC:MEOBF) CEO Silviu Itesu speaks on his company`s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that the technology implies. Itesu discusses development compound Revascor for use in congestive heart failure and details the latest Phase II results. In 60 patients the drug saw no adverse events and a 0% event rate (hospital visits, mortality) compared to 20% in a control group; the company is planning to initiate a 1500-patient Phase III study in the coming few months. The trials are funded entirely by Teva (TEVA), says Itesu, but the company`s financial situation would allow for a few years of `solo` operation.

Itesu briefly compares Mesoblast`s production strategies to those of Dendreon`s (DNDN) Provenge, and explains how Mesoblast`s production will be significantly less expensive. The conversation also covers two more pipeline products, a Type-2 diabetes treatment and an intervertebral disc treatment, both of which have shown promising results in Phase II studies.

Click Here to view our video interview of Mesoblast CEO Silviu Itesu.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://propthink.com

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PropThink via Thomson Reuters ONE HUG#1625942

The rest is here:
Mesoblast Interview: The Best Adult Stem Cell Technology In The World?